Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Donanemab in Healthy Participants
NCT05567159Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2022
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of donanemab in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to Four Weeks, Maximum Observed Concentration During a Dosing Interval at Steady State at Day 71 and 1 more. Started Oct 2022; status: completed.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05567159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05567159.